Chemical cytometry for neoplasia prognosis-Barrett's esophagus

化学细胞术用于肿瘤预后-巴雷特食管

• 批准号: 7238995
• 负责人: Norman J Dovichi
• 金额: $ 30.88万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-01 至 2010-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7238995
• 关键词: Acids; Address; Adenocarcinoma; Algorithms; Archives; Barrett Esophagus; Biogenic Amines; Biological; Biological Assay; Biological Markers; Biological Models; Biometry; Biopsy; Blood capillaries; Boston; Capillary Electrophoresis; Cations; Cell Count; Cell Cycle; Cell Differentiation process; Cells; Cessation of life; Chemicals; Chemistry; Classification; Clinical; Coin; Complication; Condition; Cytometry; Cytoskeletal Proteins; DNA; DNA Damage; Data; Data Quality; Detection; Development; Diagnosis; Direct Costs; Disease; Disease Outcome; Disease Progression; Dysplasia; Early Diagnosis; Emerging Technologies; Endoscopy; Epithelium; Esophageal; Esophageal Adenocarcinoma; Esophagus; Ethanol; Evolution; Excision; Fingerprint; Fluorescence; Fred Hutchinson Cancer Research Center; Frequencies; Funding; Future; General Population; Genomic Instability; Goals; Grant; Head; Health Professional; Heterogeneity; Hospitals; Human Genome Project; Image Cytometry; Imagery; Incidence; Individual; Intestinal Metaplasia; Label; Lasers; Length; Life; Malignant Neoplasms; Measurement; Medical Surveillance; Modeling; Molecular; Molecular Genetics; Monitor; NIH Program Announcements; Neoplasms; Numbers; Oncologist; Operative Surgical Procedures; Outcome; Pathologist; Pathology; Patients; Phase; Phosphorylation; Pilot Projects; Precancerous Conditions; Principal Investigator; Progress Reports; Proteins; Rate; Recording of previous events; Reflux; Reporting; Reproducibility; Request for Applications; Research; Research Personnel; Research Project Grants; Resources; Science; Score; Serum; Serum Markers; Services; Staging; Standards of Weights and Measures; Stem cells; Study Section; Surface; System; Technology; Testing; Therapeutic; Time; United States; United States National Institutes of Health; Universities; Validation; Variant; Washington; Woman; Work; analytical tool; anticancer research; base; capillary; cell fixing; cohort; design; experience; follow-up; gastrointestinal; improved; medical schools; member; mortality; new technology; outcome forecast; professor; programs; protein expression; research study; response; single cell analysis; tool; two-dimensional

DESCRIPTION (provided by applicant): This application is in response to RFA-CA-06-003, Applications of emerging technologies for Cancer Research. This RFA:" invites applications for research projects to evaluate the usefulness of emerging molecular technologies that are ready for initial application to clinical or biological questions in cancer research. Projects should be designed to demonstrate that the technology is robust and yields reproducible measurements. Projects should also be designed to gather preliminary data to support the use of the technology in a future project(s) with a clinical or biological focus." The application combines the efforts of researchers in the Departments of Chemistry and Pathology at the University of Washington and at the Fred Hutchinson Cancer Research Center. These researchers will perform a pilot study to evaluate new technology for cancer research, chemical cytometry. This technology monitors protein and biogenic amine expression in single cells, and will be evaluated for the study of cells isolated from biopsies obtained from patients in the Seattle Barrett's Esophagus Cohort. We will systematically determine the variance in cellular composition within Barrett's esophagus biopsies We will dissect 20 cells from a single crypt isolated from a biopsy and perform chemical cytometry on those cells. This study will provide understanding of the variance in protein expression along a crypt and during development of a stem cell into its differentiated form. We will perform chemical cytometry on cells isolated from three crypts obtained from a single biopsy. These crypts will be closely related and the study will provide information on the intraclonal variation. We will perform chemical cytometry on cells isolated from crypts obtained from three biopsies from the same patient. This study will provide information on the interclonal variation. We will generate fingerprints from 5 patients, which will provide information on the between-patient variance. As a result of these studies, we will have identified the number of cells or crypts necessary to be assayed to characterize the neoplasia. Based on these results, we will propose a follow-up grant for the systematic validation of chemical cytometry for prognosis of the progression to adenocarcinoma, and for the development of a platform appropriate for large-scale clinical analysis.

描述（由申请人提供）：此应用是响应RFA-CA-06-003，即新兴技术用于癌症研究的应用。此RFA：“邀请研究项目的申请，以评估新兴分子技术的实用性，这些技术准备在癌症研究中最初应用于临床或生物学问题。应设计项目以证明该技术是可行的，并且应产生可再现的测量值。项目也应旨在在未来的临床或临床上旨在收集该技术的预定数据，以收集临床或临床的焦点。该应用程序结合了华盛顿大学化学和病理学系和弗雷德·哈钦森癌症研究中心的研究人员的努力。这些研究人员将进行一项试点研究，以评估用于癌症研究的新技术，化学细胞仪。该技术可以在单个细胞中监测蛋白质和生物胺的表达，并将评估从西雅图Barrett的食管同伴中从活检中分离出的细胞。我们将系统地确定Barrett食管活检中细胞组成的方差，我们将从活检中分离出的单个隐窝中剖析20个细胞，并对这些细胞进行化学细胞仪。这项研究将提供对沿隐窝和干细胞开发为分化形式的蛋白质表达方差的理解。我们将对从单个活检获得的三个隐窝分离的细胞进行化学细胞仪。这些隐窝将密切相关，研究将提供有关隆内变异的信息。我们将对从同一患者的三个活检中获得的隐窝分离的细胞进行化学细胞仪。这项研究将提供有关克隆变化的信息。我们将产生5例患者的指纹，这些指纹将提供有关患者间差异的信息。由于这些研究，我们将确定对肿瘤症表征所必需的细胞或隐窝数量。基于这些结果，我们将为对化学细胞仪进行系统验证的后续赠款，以预测对腺癌的进展，以及开发适合大规模临床分析的平台。